Is Eli Lilly using ‘granfluencers’ to raise awareness of its Alzheimer’s med?
By
Marc Iskowitz
Sep 04, 2024
Here’s why older internet celebs — granfluencers — soon might be making rounds on the Alzheimer’s drug marketing scene.
Psychological well-being declines years before diagnosis of MCI
Aug 20, 2024
The findings were seen specifically for the components of purpose in life and personal growth.
Lutheran Senior Services opens Netherlands-inspired dementia village, with more on the way
By
Kimberly Bonvissuto
Jul 30, 2024
Inspired by a dementia village model in the Netherlands, a US senior living operator is opening a new memory care neighborhood concept in two of its communities to provide a “safe and immersive” experience...
What happens if biomarker tests spot Alzheimer’s before people show symptoms?
By
Kristen Fischer
Aug 05, 2024
As of now, no therapy is approved by the Food and Drug Administration for people at risk of Alzheimer’s disease who don’t have symptoms. But blood tests that can spot biomarkers linked to the disease...
New practices, strategies help improve life for those with dementia, caregivers: report
By
Kimberly Bonvissuto
Jul 26, 2024
New practices and strategies are helping senior living communities improve the everyday lives of residents living with dementia and their caregivers, according to a new report from Sodexo that aims to...
Communities break fundraising record during The Longest Day
By
Foster Stubbs
Jul 24, 2024
63 Charter Senior Living communities across the nation raised money for Alzheimer’s research as part of the Alzheimer’s Association’s The Longest Day initiative. Find out more, and learn how to submit...
Senior living providers embrace role in CMS dementia care pilot program
By
Kimberly Bonvissuto
Jul 11, 2024
Senior living providers named participants in the federal government’s new dementia care pilot program said they are excited to be part of a new effort to support people living with dementia and their...
FDA delays decision on new Alzheimer’s drug
Mar 08, 2024
Instead of approving the new Alzheimer’s drug donanemab this month, as was expected, the U.S. Food and Drug Administration will now require the experimental medication be scrutinized more closely...
Aegis Living, SLR recognized for achieving elevated memory care standards
By
Kimberly Bonvissuto
Feb 26, 2024
Two assisted living and memory care providers have earned certifications for meeting elevated standards of care for people living with dementia.
FDA approves new drug to treat Alzheimer’s
Jul 02, 2024
In clinical trials, donanemab (Kisunla) modestly slowed the pace of thinking declines among patients in the early stages of the memory-robbing disease. But it also carried significant safety risks, including...